Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Rep. Katie Porter (D-Calif.)—minus her "Whiteboard of Justice"—speaks at the U.S. Capitol on December 19, 2019. (Photo: Alex Wong/Getty Images)

Rep. Katie Porter (D-Calif.)—minus her "Whiteboard of Justice"—speaks at the U.S. Capitol on December 19, 2019. (Photo: Alex Wong/Getty Images) 

'You Lie': Katie Porter Wields 'Whiteboard of Justice' While Grilling Pharma CEO on Price Hikes

"You're spending all this money to make sure you make money rather than spending money to... help patients," the California congresswoman told AbbVie's Richard Gonzalez.

Brett Wilkins

U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.

"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
—Rep. Katie Porter

Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez—whose total compensation topped $24 million last year (pdf)—about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.

Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug. 

In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.

Porter (D-Calif.) pointed out that the company spends nearly double that—$4.7 billion—annually on advertising. 

When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."

"Try $334 [million] on for size," Porter shot back.

Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."

"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.

"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."

"The fact [is] that you're not honest about that with patients and policymakers—that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

Because Climate Science 'Does Not Grade on a Curve,' Experts Says IRA Not Enough

"There is an urgent need for much more aggressive and far-reaching measures to prevent climate chaos," said the head of one progressive consumer advocacy group.

Brett Wilkins ·


'Game-Changer and Reason for Hope': House Passes Inflation Reduction Act

"We've got more to do," Rep. Pramila Jayapal said on the House floor. "But today, let's celebrate this massive investment for the people."

Jake Johnson ·


'This Is Insane': Search Warrant Indicates FBI Investigating Trump for Espionage Act Violation

"If you're not fed up," said watchdog group Public Citizen, "you're not paying enough attention."

Jessica Corbett ·


Anti-War Veterans Group Asks Biden to 'Read Our Nuclear Posture Review Before Releasing Yours'

"Are you willing to risk a civilization-ending apocalypse by playing nuclear chicken with other nuclear-armed nations? Or will you lead us toward a planet that is free of nuclear weapons?"

Jessica Corbett ·


'Big Win' for Public Lands and Climate as US Judge Reinstates Coal Lease Ban

"It's past time that this misguided action by the Trump administration is overturned," said one environmental campaigner.

Brett Wilkins ·

Common Dreams Logo